Colorful, surgeons call it “Princess”

The functional neurosurgery experts in our hospital operate with the assistance of rosa
ROSA is a multi-functional robot from France. The full English name is (Robot of Surveillance Assistant). Different from the image of ordinary robots, ROSA has soft lines and gorgeous colors. Its whole body is covered with rose colored ribbons. Neurosurgeons affectionately call it “Princess ROSA”. The little princess is not arrogant at all. She works quickly and beautifully. Its arms are free and flexible, and its hands are “fast and accurate”. Zhang Rui, director of functional neurosurgery and chief physician of Nanjing Brain Hospital, revealed that ROSA’s mechanical arm is equipped with a sensing device that can automatically track the patient’s position. “It integrates preoperative planning software, navigation and tracking functions, robot assisted device positioning and operating system, and advanced visualization functions.” ROSA can quickly capture and locate the lesions in the patient’s brain with an error of less than 1mm. However, in traditional surgery, there is a complex process to locate the brain lesions. Doctors often need to use X and Y field operations on the operating table to obtain the precise location of the lesions. And every time you look, you need to adjust the patient’s brain posture and recalculate. “It can be said to do math problems while performing surgery.” Director Zhang Rui smiled. Since Princess ROSA “arrived”, the problem of precise positioning has been solved, and doctors only need to focus on the operation itself. “This greatly shortens the operation time and is at least twice as fast as the traditional operation. The patient’s trauma is smaller.”

Eight electrodes were implanted in the brain, and the operation was shortened to 2 hours

After coming to Nanjing, ROSA has assisted experts in functional neurosurgery in the brain hospital to perform many operations. Ms. Wang, a 32 year old epileptic, had received stereotactic electrode implantation with the help of ROSA robot a few days ago. Director Zhang Rui said that epilepsy, commonly known as “epilepsy” or “epilepsy”, is a chronic disease that causes transient brain dysfunction due to sudden abnormal discharge of brain neurons. About 30% of drug-resistant patients need surgery to relieve their pain, and Ms. Wang is one of them. When Ms. Wang was 17 years old, she was diagnosed with epilepsy. During the seizure, she frothed at the mouth and twitched all over. As the course of the disease continued, her symptoms became more and more serious. It was time for surgery. The electrode implantation operation is to implant the electrode into Ms. Wang’s brain lesion, adjust the electric wave and restore the brain function. The surgery requires high accuracy of the lesions, and ROSA has the opportunity to show its skills. The expert worked out the operation plan through the preoperative planning software, and ROSA called navigation to track and locate the 8 lesions in Ms. Wang’s brain. “Through minimally invasive surgery, 8 electrodes were rapidly implanted into 8 lesions.” Director Zhang Rui said that the operation time was shortened to 2 hours, while it would take half an hour for traditional surgery to implant an electrode. “Precise, minimally invasive and efficient, this is the arrival of ROSA robot, which brings significant changes to brain surgery.”

It is also a good helper to equip the brain with a pacemaker

Deep brain stimulation, commonly known as brain pacemaker (DBS), is a landmark new technology in surgical treatment of Parkinson’s disease. This technology can significantly improve the symptoms of movement retardation, muscle stiffness or tremor of Parkinson’s patients, and can also significantly reduce the side effects of taking drugs. The operation is very difficult and golden. ROSA robot has assisted Zhang Wenbin, deputy director of functional neurosurgery and chief physician of Nanjing Brain Hospital, to perform DBS operation for two Parkinson’s patients. Zhang Wenbin, the chief physician, explained that DBS therapy is mainly to implant brain pacemakers into the patient’s brain, stimulate some nerve nuclei in the deep brain, correct abnormal brain electrical circuits, and reduce these neurological symptoms. “The more accurate the implantation of brain pacemaker, the better the effect. The arrival of ROSA has greatly improved the accuracy.” The reporter learned that ROSA will also be used in tumor interstitial chemotherapy, brain tumor localization and biopsy, hematoma drainage, cyst drainage and other fields in the future.
Are ROSA robots at risk
Robots operate on the human brain. It sounds terrible. Is this operation risky? Zhang Wenbin explained that ROSA is a functional auxiliary robot whose main function is precise positioning. The brain surgery is still completed under the guidance of doctors, so ROSA will not damage the brain, on the contrary, it greatly improves the surgical accuracy.
Is the surgery expensive
How much will the cost of surgery increase after ROSA joins? Director Zhang Rui said that this is the first ROSA robot introduced in Jiangsu, and the price department has not yet approved the charging standard. At present, ROSA robots do not charge extra. The future charges shall be subject to the provisions of the price department.

@MasimoInnovates | #Masimo

About Masimo

Masimo (NASDAQ: MASI) is a global leader in innovative non-invasive monitoring technology. Our mission is to improve patient outcomes and reduce treatment costs by introducing non-invasive monitoring into new sites and applications. In 1995, the company launched Masimo SET ? Mobile and Low Perfusion (Measurement under low perfusion) Pulse oxygen saturation meter. Several studies have shown that this instrument can greatly reduce false alarms and accurately monitor true alarms. Masimo SET ? It is estimated that it has been applied to more than 100 million patients in the world’s leading hospitals and other medical institutions. In 2005, Masimo launched rainbow ? The technology of pulse carbon oxygen saturation meter realizes non-invasive continuous monitoring of blood components that can only be measured invasively in the past, including total hemoglobin (SpHb ?)、 Oxygen content (SpOC )、 Carboxyhemoglobin (SpCO ?)、 Methemoglobin (SpMet ?) And the latest Pulse Perfusion Variability Index (PVI ?) And oxygen reserve index (ORI )， There are also SpO2, pulse rate and perfusion index (PI). In 2014, Masimo launched Root ?， This is an intuitive patient monitoring and connection platform, equipped with Masimo Open Connect (MOC-9 ) Interface. Masimo also relies on Radius 7 in the field of mHealth Wearable patient monitor and MightySat Fingertip pulse oxygen saturation meter and other products play an active leading role. For further information on Masimo and its products, please visit www.masimo.com. All published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm 。

Forward looking statements

This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include SedLine regarding Masimo ? And O3 Statement of potential efficacy of technology, etc. These forward-looking statements are based on current expectations of future events that affect us, and are subject to risks and uncertainties. All risks and uncertainties are difficult to predict, most of which are beyond our control, and may lead to our actual results being significantly different and diametrically opposite to those stated in our forward-looking statements, due to various risk factors, Including but not limited to risks related to the following factors: our assumptions about the repeatability of clinical results; Our belief in Masimo’s unique non-invasive measurement technology includes: Masimo’s SedLine related to positive clinical outcomes and patient safety ? And O3 Technology; Our belief in Masimo’s non-invasive medical breakthrough to provide cost-effective solutions, which have the same accuracy and unique advantages, including immediate and continuous results, can achieve early treatment, and will not cause invasive trauma in all patients and each clinical situation; And other factors discussed in the “Risk Factors” section of our latest report to the Securities and Exchange Commission (“SEC”), which is available free of charge on the SEC’s website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct in the future. All forward-looking statements contained in this press release are in full compliance with the foregoing cautionary statements. We would like to remind you not to unduly rely on these forward-looking statements, which are only applicable today. Except as may be required by applicable securities laws, we have no responsibility to update, amend or clarify these statements or the “risk factors” contained in our latest report to the SEC, whether as a result of new information, future events or other matters.

The original version can be found on businesswire.com: http://www.businesswire.com/news/home/20160707005661/en/

Disclaimer: The original version of this announcement is officially authorized. The translation is only for the purpose of understanding. Please refer to the original version, which is the only version with legal effect.

1. Abbott

FreeStyle Libre: Flash glucose monitoring system
Abbott’s FreeStyle Libre system is a glucose measurement system that does not require finger stick or finger stick calibration. It measures blood sugar level through a small sensor applied to the back of the user’s upper arm. According to the company, the sensor is a quarter of the size of two stacks and can provide real-time readings for up to 10 days. The sensor can also read glucose levels from clothing.
Each scan provides three data, including real-time glucose results, eight hour historical trends and trend arrows showing the direction of its glucose advance. The accompanying touchscreen reader can store up to 90 days of data so that people can track glucose levels over time.

2. Boston Science

Axios: bracket and electric cautery enhanced conveying system
Boston Scientific’s Axios stent and electrocautery enhanced delivery system are designed to provide therapeutic endoscopes with safety, accurately collecting fluid from the gastrointestinal tract into the pancreas and placing Axios stents. The system uses a cautery catheter with a therapeutic Axios stent for non exchange surgery.
Under the guidance of EUS, Axios catheter is powered through the tissue wall and enters the target structure. The conduit jacket retracts, allowing the bracket to unfold. The extraction system is then revoked.

3. Boston Science

Telescope
SpyGlass of Boston Scientific is a direct visualization system for cholangiopancreatoscopy. According to the company, it aims to optimize program efficiency and productivity because it improves ease of setup, ease of use and image quality.
It has a one-time use range, which can eliminate the reprocessing of optical probes, and reduce the risk of cross contamination and image quality degradation during multiple use. The integrated digital sensor has higher resolution image quality and 60% wider field of view, which can effectively evaluate pipes with consistent joint directions and attachment exit points. It also has special irrigation and suction connections, allowing doctors to better control and effectively clear vision. According to the company, the tip of the tapered catheter has a non-invasive design that can assist in intubation and through strict stenosis.
SpyGlass provides enhanced visualization and access for diagnostic and therapeutic applications, such as biliary system cancer, pancreatic cancer, carcinomatous duct cancer, gallbladder cancer, intraductal pancreatic mucinous tumors, intraductal papillary mucinous tumors of the pancreas, gallstones, primary sclerosing cholangitis, pancreatitis, pancreatic stones/fragments, biliary papillomatosis, and uncertain pancreatic strictures and masses.

4. Boston Science

Watchers
Boston Scientific’s Catcher is a left atrial appendage closure device that helps reduce the risk of stroke. For patients with non valvular atrial fibrillation, it can replace long-term warfarin treatment.
According to the company, Boston Science’s Watchman device is provided by way of a transfer road, which is designed to shut down the left atrial appendage to prevent thrombus migration. Because it prevents blood clots, the device can reduce the risk of stroke and systemic embolism.

5. Brainscope

BrainScope One
The BrainScope One system of BrainScope is an easy-to-use, non-invasive handheld platform that allows doctors to assess head injuries at the point of care.
The device is FDA approved and based on EEG technology. BrainScope One is non-invasive and painless, and can be used for patients aged between 18 and 85 years within three days after head injury. It measures and explains brain activity and neurocognitive function to help doctors make clinical diagnosis.

6. Basic medicine

FoundationOne CDx
FoundationOne CDx is an FDA approved extensive concomitant diagnosis for solid tumors, including colorectal cancer, breast cancer, ovarian cancer and melanoma. According to the company, it aims to provide doctors with clinically actionable information.
Each test has the burden of microsatellite instability and tumor mutation, which is helpful for making immunotherapy decisions.

7. Integra Lifesciences

Omnigraft skin regeneration matrix
Omnigraft dermal regeneration matrix of Integra Lifesciences is an advanced double-layer dermal regeneration matrix, which can treat diabetic foot ulcers. According to the company, it is the only FDA approved product that can regenerate natural dermal tissue.
The patch has a built-in silicone layer, which can be used as a temporary skin layer to provide instant coverage for wound protection. It can be deleted within two to three weeks. Underneath the siloxane layer is the collagen/chondroitin-6-sulfate matrix, which serves as a real skin substitute layer. Omnigraft has bioengineered scaffold, which can promote skin regeneration, and has controllable porosity and degradation rate.
Omnigraft dermal regenerative matrix is designed to treat partial and full thickness neurodiabetic foot ulcers that last more than six weeks without capsules, tendons or bones.

8. Koning Corporation

KBCT 1000
Koning’s KBCT is a breast imaging device. It provides high contrast, real three-dimensional breast images with spatial resolution, no painful compression in 10 second exposure, and its radiation level is the same as that of normal mammograms.
Real 3D images have isotropic images in the 3D display to allow clinicians to evaluate tissues from any angle while eliminating overlapping structures. The 3D scan of KBCT is non contrast, and the contrast is enhanced, showing blood vessels and calcification.

9. Medtronic

Implantation system for Remodulin
Medtronic’s Remodulin implant system is designed to treat patients with pulmonary hypertension. The system uses the company’s SynchroMed II implantable drug infusion pump, equipped with a newly developed intravascular catheter, which can deliver Remodulin through the external infusion pump to the vein of patients who have previously received the drug.
Medtronic announced on July 31 that the system had been approved by FDA.

10. Otsuka Pharmaceutical

Abilify MyCite
Abilify MyCite is a prescription drug with sensors that are used to treat many diseases, including schizophrenia, type I bipolar disorder and major depression.
The Abilify MyCite system tracks whether drugs have been taken. Ingestion can usually be detected within 30 minutes, but it may take up to two hours for a smartphone application or Web portal to detect whether a drug has been taken.

Masimo (NASDAQ stock code: MASI) today announced that its Root (R) patient monitoring and connection platform won the gold medal of the 2015 Medical Design Excellence Award, which is the highest award in the category of comprehensive medical devices and therapeutic products. At an award ceremony of the 2015 Western Medical Device Design Expo (www.MDMEAst. com) held at the Jarvitz Convention and Exhibition Center in New York City, the winner of the 2015 Gold Medal for Excellence in Medical Design received the award.
Root can be used with the base of the Radical-7 (R) handheld monitor or the Radius 7 (R) wearable monitor, an instant result display screen and multiple network/connection options. It can centralize multiple data streams onto a convenient and readable touch screen.

Root’s innovations include:

·MOC-9 (TM) – Enhance the measurement flexibility, and expand the measurement function of the platform by configuring MCINO Open Connect (TM) (MOC-9 (TM)) with MCINO MOC-9 module or third-party measurement equipment of other companies. A 510 (k) license is required for the new MOC-9 module to enter the US market.
·ISA (TM) CO2 map – ISA (TM) CO2 sidestream module has fast warm-up function and innovative and cost-effective Nomoline (TM) sampling pipeline
·The SedLine (R) brain function monitoring module provides four channel EEG, which can help clinicians better understand the role of anesthesia on the brain.
·Iris (TM) connection gateway is designed to integrate independent infusion pumps, ventilators, beds and other patient monitoring devices. Iris can enable Root to read the data of all devices connected to the patient and act as the indoor patient monitor and connection center. The alerts and alarms sent by all devices are seamlessly forwarded to the patient’s clinician, and the data of all devices are easily recorded in the patient’s electronic medical record.
·Wireless – able to transfer information via Bluetooth and Wi Fi

Root is applicable to Radical-7 or Raidus-7. Raidus-7 is the first and only wearable wireless monitor. With the groundbreaking rainbow (R) SET (R) technology of Maxino, it can measure blood oxygenation, pulse rate and rainbow (R) acoustic monitoring (RAM (TM)) via acoustic respiration rate (RRa (R)). Radius 7 can provide continuous monitoring for patients who are free to move, allowing hospitals to optimize their ability to get patients out of bed as soon as possible. Research shows that exercise is a key factor for patients to recover more easily (1).

The Medical Design Excellence Award Competition (www.MDEAwards. com), organized and implemented by UBM Canon, is the only award program to recognize the contribution and promotion of medical product design. The selection of products for the competition is based on their design and engineering characteristics, including innovative use of materials, user related functions that can improve medical services and change traditional medical attitudes, features that bring higher benefits to patients, and the ability of product development teams to overcome design and engineering challenges and make products meet clinical requirements. The participating products will be comprehensively evaluated by a multidisciplinary team composed of third-party judges involving biomedical engineering, human factors, industrial design, medicine and diagnostics.

Joe Kiani, founder and CEO of Maxino, said: “We are very honored that Root won the Gold Medal of Excellence in Medical Design in 2015. We hope that Root will remove the barriers to connecting innovative products and interoperability, and automate patient monitoring with an open and scalable architecture.”

(1)Needham D，Korupolu R，Zanni J，Pradhan P，Colantuoni E，Palmer J，Brower R，F(xiàn)an E。 “Early physiotherapy and rehabilitation of patients with acute respiratory failure: a quality improvement plan”. Journal of Physiotherapy and Rehabilitation Medicine Vol. 91, No. 4, pp. 536-542, April 2010

About Maxino

Masimo (NASDAQ stock code: MASI) is a global leader in innovative non-invasive detection technology. Its technology has greatly improved the therapeutic effect – solving the “unsolvable” problem. In 1995, the company launched the Measure Through Motion and Low Perfusion (Masimo SET (R)) pulse oximeter, which can be measured under the condition of exercise and low blood perfusion. This product almost eliminated false positives and improved the ability of pulse oximetry technology to detect life threatening events. More than 100 independent and objective studies have shown that Masimo SET (R) outperforms other pulse oximetry techniques, even under the most challenging clinical conditions, including patient displacement and low blood perfusion. In 2005, Maxino launched rainbow Pulse CO Oximetery technology, which can monitor blood components non invasively and continuously, but previously this could only be measured by invasive methods; In addition to measuring SpO2, pulse rate and blood perfusion index (PI), this technology can also measure total hemoglobin (SpHb (R)), blood oxygen content (SpOC (TM)), carboxyhemoglobin (SpCO (R)), methemoglobin (SpMet (R)) and perfusion variability index (PVI (R)). To learn more about Maxino and its products, please visit: www.masimo com 。@ masimoinnovates

Forward looking statements

This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on our current expectations of future events that affect us and are subject to risks and uncertainties. It is difficult for us to predict these risks and uncertainties, many of which are beyond our control, and may lead to substantial and adverse differences between the actual results and those predicted in our forward-looking statements. Various risk factors include those discussed in the “Risk Factors” section of our recent report to the Securities and Exchange Commission (SEC) (the report can be freely viewed from the SEC website at www.sec.gov). Although we believe that our expectations in forward-looking statements are reasonable, we do not know whether our expectations can be proved to be correct. All forward-looking statements contained in this press release are applicable to the above cautionary statements. Readers should not rely too much on these forward-looking statements, which are only statements as of the date of publication. Unless required by applicable securities laws, we do not assume the obligation to update, revise or clarify these forward-looking statements or the “risk factors” in our latest report to the Securities and Exchange Commission, regardless of whether new information or future events occur.

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care by Taking Nonvolatile Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet and PVI are trademarks or registered trademarks of Maxino.